Company intelligence / Profile preview
Refreshgene Therapeutics
Shanghai, Chinarefreshgene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Refreshgene has shown efficacy in restoring hearing in five out of six deaf children in a trial. Their lead product RRG001 for wet AMD is in Phase 1/2 trials in China, and RRG-003 for deafness is in Phase 1 trials. RRG-OTOF has received FDA Rare Pediatric Disease Designation and Orphan Drug Designation.
- Therapeutic areas
- CardiovascularMetabolic DisordersOphthalmologyOncologyNeurology
- Modalities
- AAV-based gene therapyDual Vector AAV
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
OBiO Technology Corp., Ltd.PackGene Biotech
Beyond the preview
Go deeper on Refreshgene Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Refreshgene Therapeutics.